Nectar Lifescience's Q4 FY 2025-26 Quarterly Results

Result Summary

• Nectar Lifescience Ltd reported a 1048.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 98.2%.
• Its expenses for the quarter were up by 100.3% QoQ and down 89.6% YoY.
• The net profit decreased 576.0% QoQ and decreased 47.8% YoY.
• The earnings per share (EPS) of Nectar Lifescience Ltd declined at 3.38 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Nectar Lifescience Ltd is a company primarily involved in the pharmaceutical industry. The company focuses on the development, production, and marketing of active pharmaceutical ingredients (APIs), finished formulations, and phytochemicals. As a significant player in the pharmaceutical sector, Nectar Lifescience Ltd serves both domestic and international markets, offering a range of products that cater to diverse medical needs. However, specific recent developments or strategic initiatives undertaken by the company are not available within the provided data.

Revenue

During the fourth quarter of the fiscal year 2026, Nectar Lifescience Ltd reported a total income of ₹7.58 crores. This represents a substantial quarter-over-quarter increase of 1048.5% compared to ₹0.66 crores in the third quarter of FY26. However, when compared on a year-over-year basis, there is a significant decline of 98.2% from ₹430.77 crores in the fourth quarter of FY25. These figures highlight the variability in revenue generation for Nectar Lifescience Ltd over the specified periods.

Profitability

Nectar Lifescience Ltd's profitability metrics for Q4FY26 reveal a challenging financial performance. The company recorded a loss before tax of ₹56.93 crores, contrasting with a profit of ₹56.60 crores in Q3FY26, indicating a quarter-over-quarter decrease of 200.6%. When compared year-over-year, the loss before tax decreased by 69.7% from a loss of ₹187.66 crores in Q4FY25. The profit after tax was a loss of ₹67.92 crores in Q4FY26, which is a significant decline from a profit of ₹14.27 crores in Q3FY26 and a 47.8% improvement from a loss of ₹130.09 crores in Q4FY25. The earnings per share (EPS) in Q4FY26 was reported at ₹-3.38, a notable decline from ₹0.64 in Q3FY26, yet a 41.7% improvement from ₹-5.80 in Q4FY25.

Operating Metrics

The total expenses for Nectar Lifescience Ltd in Q4FY26 amounted to ₹64.51 crores, which is a 100.3% increase from ₹32.20 crores in Q3FY26. When compared to Q4FY25, there is an 89.6% decrease from ₹618.44 crores. The tax expense for the fourth quarter of FY26 was reported as a negative ₹19.72 crores, marking an increase of 78.9% from a negative ₹11.02 crores in the previous quarter, and a 65.8% decrease from a negative ₹57.58 crores in the same quarter last year. These figures reflect the financial dynamics and cost structure fluctuations experienced by Nectar Lifescience Ltd during the specified periods.